The European Association of Nuclear Medicine (EANM) is participating in a European intersocietal consensus project that will describe the use of biomarkers of neurocognitive disorders in mild cognitive impairment and stages of mild dementia.
The initiative consists of a task force of 11 other European scientific societies. On 9 October, the task force published a document outlining its efforts in Alzheimer's & Dementia.
